Clinical Characteristic and Prevalence of Invasive Candidiasis Patient

Abstract

Introduction Invasive candidiasis is a significant cause of morbidity and mortality, particularly in the intensive care unit (ICU). The clinical landscape is complicated by a shifting epidemiology, including the rise of non-albicans species and increasing antifungal resistance. This review synthesizes evidence on the clinical characteristics, prevalence,

and management challenges of this infection.

Methods This literature review analyzes eight key articles published between 2010 and 2024. The analysis examines the evolving epidemiology of

Candida species, key risk factors for infection, the utility of diagnostic tools, and treatment challenges in vulnerable patient populations.

Results A primary finding is the epidemiological shift from Candida albicans to non-albicans species like C. glabrata and C. parapsilosis, which now cause over 50% of candidemia cases in some ICUs. This shift complicates treatment due to varying resistance profiles. Key risk factors include central venous catheters, parenteral nutrition, and prior antibiotic use. Mortality rates remain high, often exceeding 40%, exacerbated by antifungal resistance and delays caused by insensitive diagnostic methods.

Discussion The evidence indicates a "one-size-fits-all" empirical treatment for invasive candidiasis is no longer adequate due to the rise of resistant non-albicans species. High mortality is directly linked to diagnostic delays that postpone appropriate therapy. This necessitates a paradigm shift towards proactive management based on local epidemiological surveillance and risk assessment.

Conclusion To combat invasive candidiasis, rapid and accurate diagnostic tools are urgently needed. Effective management requires vigilant local epidemiological surveillance, patient risk stratification, and tailored antifungal stewardship programs to improve outcomes and address increasing resistance.